Peptide Intelligence · peptide
Tesamorelin
Also: Egrifta
A growth-hormone-releasing-hormone analog. Approved to reduce excess abdominal fat in people with HIV-associated lipodystrophy; used off-label for fat loss and body composition.
Approval status
FDA-approved
Reduction of excess abdominal fat in HIV-infected adults with lipodystrophy (Egrifta).
Compounding status
Approved product
Use outside the approved indication is off-label and is a clinician decision.
Evidence grade
A · Human randomized trials
RCTs in the approved indication; little controlled data for other uses.
Known risks and label warnings
- IGF-1 elevation; fluid retention; injection-site reactions; glucose intolerance
- Contraindicated in active malignancy and pregnancy
Interactions people ask about
- Glucocorticoids; drugs metabolized by CYP450 (label)
What people often measure
Framed as things to discuss with your clinician, not a protocol.
- IGF-1
- Fasting glucose or A1c
- Waist and body composition
Questions for your clinician
- Should IGF-1 and glucose be checked while I take this?
Get the full report by email
- The Tesamorelin status card, monitoring list and clinician questions, printable
- The pre-therapy baseline checklist: what people commonly measure before starting any injectable
- A note the next time FDA or HHS acts on this compound
Wellness guidance only, not medical advice. We never sell or dispense medication.
Sources and review
Status as of 2026-09-02. Reviewed 2026-09-02 by Curtis Holder (product); clinical review pending; next review due 2026-12-01. Regulatory status changes; we update this page after each FDA or HHS action. Wellness guidance only, not medical advice. Med.xyz does not sell, prescribe or recommend any compound.